New monoclonal antibodies against bilitranslocase as a diagnostic tool in determining the progress of clear cell renal cell carcinoma
Abstract
Background: Monoclonal antibodies (mAbs) are an important tool in diagnostics and research, especially when we are dealing with a protein marker of unknown primary structure as in the case of bilitranslocase (BTL). BTL is also expressed on kidney cells, where it acts as an organic anion transporter. We have shown earlier that there are differences in bilitranslocase expression in normal kidney cells versus early grade kidney cancer.
Methods: We developed monoclonal antibodies against extra- and intra-cellular domains of bilitranslocase protein model. To also gain a deeper insight in bilitranslocase expression in clinical samples, we assessed BTL expression in different grades of clear cell kidney cell carcinoma (ccRCC).
Results: Both new monoclonal antibodies bind to a protein in UOK171 cells but not in the negative control. Binding of mAb is specifc. mAb produced by cell line 2A9/2E9 (peptide 298–310; intracellular domain) is more suitable for immunohistochemical analyses as it gives stronger intensity of binding than mAb produced by cell line 11C9/2G9 (peptide 235–246; extracellular domain). Antibody 2A9/2E9 stains bilitranslocase in proximal renal tubules of normal kidneys but not in the surrounding stroma. Staining decreases in grade I compared to normal kidney, gradually increases in grades II and III, and decreases again in grade IV of ccRCC tissue.
Conclusions: Our results show that these antibodies can be used in different immunoassays. Furthermore, specificity and afnity of our mAbs allowed us to use them in the analysis of progressive grades of clear cell renal cell carcinoma in a limited number of patients. Tus, mAbs developed here can be used as a diagnostic tool that could help distinguish between early and late grades of clear cell renal cell carcinoma.
Downloads
References
Elias MM, Lunazzi GC, Passamonti S, Gazzin B, Miccio M, Stanta G, et al. Bilitranslocase localization and function in basolateral plasma membrane of renal proximal tubule in rat. Am J Physiol Renal Physiol1990;259(4 Pt 2):F559–64.
Nicolin V, Grill V, Micali F, Narducci P, Passamonti S. Immunolocalisation of bilitranslocase in mucosecretory and parietal cells of the rat gastric mucosa. Journal of Molecular Histology. 2005;36(1–2):45–50.
Maestro A, Terdoslavich M, Vanzo A, Kuku A, Tramer F, Nicolin V, et al. Expression of bilitranslocase in the vascular endothelium and its function as a flavonoid transporter. Cardiovascular Research. 2009;85(1):175–83.
Battiston L, Passamonti S, Macagno A, Sottocasa GL. Te Bilirubin-Binding Motif of Bilitranslocase and Its Relation to Conserved Motifs in Ancient Biliproteins. Biochemical and Biophysical Research Communications. 1998;247(3):687–92.
Perdih A, Roy Choudhury A, Župerl Š, Sikorska E, Zhukov I, Solmajer T, et al. Structural Analysis of a Peptide Fragment of Transmembrane Transporter Protein Bilitranslocase. PloS one. 2012;7(6):e38967.
Montanic S, Terdoslavich M, Rajcevic U, De Leo L, Department of Medical Sciences US, Curin Serbec V, et al. Development and characterization of a novel mAb against bilitranslocase–a new biomarker of renal carcinoma. Radiology and Oncology. 2013;47(2).
Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treatment Reviews. 2008;34(3):193–205.
Rajer M. Kidney cancer. Radiology and Oncology. 2007;41(2).
Cohen HT, McGovern FJ. Renal-Cell Carcinoma. New England Journal of Medicine. 2005;353(23):2477–90. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specifc approaches to therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(18 Pt 2):6282s-9s.
Linehan WM. Identifcation of the von Hippel-Lindau (VHL) Gene. Jama. 1995;273(7):564.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7(6):618–30.
DeVita TV, Hellman S, Rosenberg AS, editors. Principles and practice of Oncology 7th edition. Philadelphia: Lippincott Williams & Wilkins; 2005.
Kim WY, Kaelin WG. Role of VHL Gene Mutation in Human Cancer. Journal of Clinical Oncology. 2004;22(24):4991–5004.
Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proceedings of the National Academy of Sciences. 1996;93(20):10595–9.
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469(7331):539–42.
Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature.2010;463(7279):360–3.
Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nature Genetics. 2013;45(8):849–50.
Linehan WM, Srinivasan R, Schmidt LS. Te genetic basis of kidney cancer: a metabolic disease. Nature Reviews Urology. 2010;7(5):277–85.
Čufer T. Rak ledvic. Onkologija. 2005;9:76–9.
Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard J-J, et al. Renal Cell Carcinoma Guideline. European Urology. 2007;51(6):1502–10.
Vanzo A, Terdoslavich M, Brandoni A, Torres AM, Vrhovsek U, Passamonti S. Uptake of grape anthocyanins into the rat kidney and the involvement of bilitranslocase. Molecular Nutrition & Food Research. 2008;52(10):1106–16.
Golijanin DJ, Marshall J, Cardin A, Singer EA, Wood RW, Reeder JE, et al. Bilitranslocase (BTL) is immunolocalised in proximal and distal renal tubules and absent in renal cortical tumors accurately corresponding to intraoperative near infrared fluorescence (NIRF) expression of renal cortical tumors using intravenous indocyanine green (ICG). Te Journal of Urology. 2008;179(4):137.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
